Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

NewAmsterdam Pharma Co N.V.

NASDAQ: NAMS · Life Sciences · 5 alerts · CIK 1936258

Share price
$19.46Close, Nov 16
Market cap
$2.33B
Shares outstanding
119.93MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All NewAmsterdam Pharma Co N.V. filings on SEC EDGAR ↗

7:41 AM ET 10-Q
Financial Results

NewAmsterdam Pharma Co Q3 2026 Results: Net Loss of $17.4M, Loss Narrows

NewAmsterdam Pharma reported a net loss of $130.0 million for the nine months ended September 30, 2026, compared to $128.9 million in the prior year period. Revenue increased significantly to $25.9 million, primarily driven by $19.2 million in the third quarter, while the company maintained a strong liquidity position with $423.1 million in cash and cash equivalents.

Key figure
Net loss $17.4M
7:35 AM ET 8-K
Financial Results

NewAmsterdam Pharma Co Financial Results

NewAmsterdam Pharma reported third quarter 2026 financial results and highlighted the European Commission's approval of Ubeslo and Evlarco for hypercholesterolaemia. The company ended the quarter with $643.1 million in cash and expects an interim analysis of its PREVAIL cardiovascular outcomes trial in Q4 2026.

“The third quarter was marked by significant progress across our regulatory and clinical priorities, including the first regulatory approval of obicetrapib worldwide and the initiation of the SPINOZA Phase 2b trial in preclinical Alzheimer’s disease. Looking ahead, we anticipate reaching the predefined event number for the planned PREVAIL interim analysis in the fourth quarter, with the outcome expected in the first quarter of 2027.”

Michael Davidson, M.D., Chief Executive Officer of NewAmsterdam Pharma
4:31 PM ET Form 4
Insider Selling

NewAmsterdam Pharma Co CSO Johannes Jacob Pieter Kastelein Sells $1.26M of Stock

Johannes Jacob Pieter Kastelein, CSO, sold 50,246 shares of NewAmsterdam Pharma Co N.V. at $25.03 a share, worth $1.26M in total on Sep 30, 2026. Shares held after the trade: 69,302 (-42.0%).

Value
$1.26M
Shares
50,246
Price
$25.03
Role
CSO
Holding change
-42.0%
Trade date
Sep 30, 2026
8:23 AM ET 8-K
Business Update

NewAmsterdam Pharma Co Business Update

NewAmsterdam Pharma has dosed the first participant in its Phase 2b SPINOZA clinical trial, which evaluates obicetrapib in approximately 400 individuals with preclinical Alzheimer’s disease. The study will assess changes in blood-based biomarkers and cognitive measures over a 52-week treatment period. This expansion into Alzheimer's follows biomarker signals observed in the company's Phase 3 BROADWAY trial.

4:30 PM ET 8-K
Regulatory Approval

NewAmsterdam Pharma Co Regulatory Approval

NewAmsterdam Pharma and its partner Menarini Group received European Commission marketing authorization for Ubeslo (obicetrapib) and Evlarco (obicetrapib/ezetimibe FDC) for the treatment of hypercholesterolaemia, marking the first regulatory approval for obicetrapib worldwide. The approval triggers milestone payments to NewAmsterdam in the mid-teens of millions of euros under its existing licensing agreement with Menarini. The company remains eligible for up to €833 million in total milestones plus tiered double-digit royalties on net sales in Europe.

Counterparty
Menarini Group

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.